Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Elpis Biopharmaceuticals maintains a portfolio with 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 2 distinct art units. The prosecution involves the distinct examiner DUNN, LINDSAY MICHELLE, who is the busiest examiner and accounts for 1 pending office action. Because there are multiple examiners for the 2 pending actions, the workload is distributed across the current prosecution pipeline.
The distribution of 2 pending office actions across different art units indicates that the company is engaging with various technical sub-specialties within the Biotechnology & Pharmaceuticals sector. This requires the legal team to adapt to the specific examination styles of the examiners involved. The presence of DUNN, LINDSAY MICHELLE as a key examiner suggests a need for consistent communication across these separate matters. Managing multiple examiners simultaneously can lead to a more diversified prosecution risk profile. The current data shows a balanced distribution of work, with the busiest examiner handling 1 pending office action. This structure allows for parallel progress on different patent applications within the Biotechnology & Pharmaceuticals space.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262122 | ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FUSION PROTEINS WITH INTERLEUKIN-15, INTERLEUKIN-15 RECEPTOR ALPHA, OR INTERLEUKIN-2 | DUNN, LINDSAY MICHELLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636699 | ANTI-CD19 ANTIBODIES AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 168d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636699 | ANTI-CD19 ANTIBODIES AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 168d overdue |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262122 | ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FUSION PROTEINS WITH INTERLEUKIN-15, INTERLEUKIN-15 RECEPTOR ALPHA, OR INTERLEUKIN-2 | DUNN, LINDSAY MICHELLE | 1644 | §112 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 17636699 | ANTI-CD19 ANTIBODIES AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | §102§112Other | Non-Final OA | 168d overdue | Pending | Feb 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial